Accelerating COVID-19 Research Using Molecular Dynamics Simulation.

The COVID-19 pandemic has emerged as a global medico-socio-economic disaster. Given the lack of effective therapeutics against SARS-CoV-2, scientists are racing to disseminate suggestions for rapidly deployable therapeutic options, including drug repurposing and repositioning strategies. Molecular dynamics (MD) simulations have provided the opportunity to make rational scientific breakthroughs in a time of crisis. Advancements in these technologies in recent years have become an indispensable tool for scientists studying protein structure, function, dynamics, interactions, and drug discovery. Integrating the structural data obtained from high-resolution methods with MD simulations has helped in comprehending the process of infection and pathogenesis, as well as the SARS-CoV-2 maturation in host cells, in a short duration of time. It has also guided us to identify and prioritize drug targets and new chemical entities, and to repurpose drugs. Here, we discuss how MD simulation has been explored by the scientific community to accelerate and guide translational research on SARS-CoV-2 in the past year. We have also considered future research directions for researchers, where MD simulations can help fill the existing gaps in COVID-19 research.

[1]  Y. Sugita,et al.  Elucidation of interactions regulating conformational stability and dynamics of SARS-CoV-2 S-protein , 2021, Biophysical Journal.

[2]  R. Zhou,et al.  Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase , 2020, The journal of physical chemistry. B.

[3]  Rommie E. Amaro,et al.  Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein , 2020, ACS central science.

[4]  Gennady M Verkhivker,et al.  Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 Mpro , 2020, J. Chem. Inf. Model..

[5]  M. Abu-Farha,et al.  Higher binding affinity of furin for SARS-CoV-2 spike (S) protein D614G mutant could be associated with higher SARS-CoV-2 infectivity , 2020, International Journal of Infectious Diseases.

[6]  Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein , 2020, International Journal of Antimicrobial Agents.

[7]  T. Schlick,et al.  Biomolecular modeling thrives in the age of technology , 2021, Nature Computational Science.

[8]  M. Ahamed,et al.  Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations , 2020, European Journal of Pharmacology.

[9]  Ernesto Estrada Topological analysis of SARS CoV-2 main protease , 2020, Chaos.

[10]  Mohsen Shahlaei,et al.  Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study , 2020, Journal of biomolecular structure & dynamics.

[11]  W. B. Cardoso,et al.  Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors , 2020, Journal of Molecular Structure.

[12]  Hoang Linh Nguyen,et al.  Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations , 2020, The journal of physical chemistry. B.

[13]  Soumya Lipsa Rath,et al.  Investigation of the Effect of Temperature on the Structure of SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations , 2020, Frontiers in Molecular Biosciences.

[14]  Reaz Uddin,et al.  Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach , 2020, Journal of biomolecular structure & dynamics.

[15]  M. Amanlou,et al.  Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study , 2020, Life Sciences.

[16]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[17]  Charlotte K. Colenso,et al.  Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands binding the Free Fatty Acid Pocket of SARS-CoV-2 Spike Protein , 2020 .

[18]  A. Warshel,et al.  Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of α-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2 , 2020, Biochemistry.

[19]  Josep Ramón Goñi,et al.  Molecular dynamics simulations: advances and applications , 2015, Advances and applications in bioinformatics and chemistry : AABC.

[20]  Sanjay Kumar,et al.  An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2 , 2020, Food Chemistry.

[21]  A. Magistrato,et al.  Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations , 2020, The journal of physical chemistry letters.

[22]  C. Cappelli,et al.  Binding of SARS‐CoV‐2 to Cell Receptors: A Tale of Molecular Evolution , 2020, Chembiochem : a European journal of chemical biology.

[23]  Subhomoi Borkotoky,et al.  Computational Insight Into the Mechanism of SARS-CoV-2 Membrane Fusion , 2021, J. Chem. Inf. Model..

[24]  Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset , 2021, Computers in Biology and Medicine.

[25]  Jeffery B. Klauda,et al.  Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations , 2020, The journal of physical chemistry. B.

[26]  K. Kulkarni,et al.  An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2 , 2021, The journal of physical chemistry. B.

[27]  Richard Lavery,et al.  Significance of Molecular Dynamics Simulations for Life Sciences , 2014 .

[28]  Jiali Gao,et al.  Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions , 2020, Proceedings of the National Academy of Sciences.

[29]  B. Luan,et al.  In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease , 2020, The journal of physical chemistry letters.

[30]  F. Markowetz All biology is computational biology , 2017, PLoS biology.

[31]  Thanyada Rungrotmongkol,et al.  Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms , 2020, Biochemistry.

[32]  M. Gur,et al.  Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states. , 2020, The Journal of chemical physics.

[33]  S. Wabaidur,et al.  Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study , 2020, Journal of biomolecular structure & dynamics.

[34]  Gregory R. Bowman,et al.  The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA , 2020, bioRxiv : the preprint server for biology.

[35]  J. Abhithaj,et al.  Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target , 2020, Journal of biomolecular structure & dynamics.

[36]  Jeffery B. Klauda,et al.  Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2 , 2020, bioRxiv.

[37]  Ron O. Dror,et al.  Molecular Dynamics Simulation for All , 2018, Neuron.

[38]  Adrian J Mulholland,et al.  Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease , 2020, Journal of chemical information and modeling.

[39]  Thomas W. Linsky,et al.  De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2 , 2020, Science.

[40]  Yohei M. Koyama,et al.  Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation , 2020, Scientific reports.

[41]  T. Tripathi,et al.  Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation , 2021, Biochemical and Biophysical Research Communications.

[42]  C. Patel,et al.  In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing , 2020, Journal of Infection and Public Health.

[43]  D. Suárez,et al.  SARS-CoV-2 Main Protease: A Molecular Dynamics Study , 2020, J. Chem. Inf. Model..

[44]  T. Tripathi,et al.  High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance , 2020, iScience.

[45]  Chao Zhang,et al.  Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM , 2020, Science Advances.

[46]  Muhamed Amin,et al.  Comparing the Binding Interactions in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV , 2020, The journal of physical chemistry letters.

[47]  Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein , 2020, PLoS pathogens.

[48]  T. Tripathi,et al.  Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity? , 2020, ACS pharmacology & translational science.

[49]  Alicia Jiménez-Alberto,et al.  Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors , 2020, Computational Biology and Chemistry.

[50]  Nicholas Y. Palermo,et al.  Targeting SARS-CoV-2 Receptor Binding Domain with Stapled Peptides: An In Silico Study , 2021, The journal of physical chemistry. B.

[51]  Gennady M Verkhivker Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins , 2020, Journal of proteome research.

[52]  M. Olvera de la Cruz,et al.  Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites , 2020, ACS nano.

[53]  Hamid Hadi-Alijanvand,et al.  Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes , 2020, Journal of proteome research.

[54]  The Answer Lies in the Energy: How Simple Atomistic Molecular Dynamics Simulations May Hold the Key to Epitope Prediction on the Fully Glycosylated SARS-CoV-2 Spike Protein , 2020, The journal of physical chemistry letters.

[55]  M. Nikfar,et al.  Small molecule therapeutics to destabilize the ACE2-RBD complex: A molecular dynamics study , 2021, Biophysical Journal.

[56]  Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein , 2020, Journal of Computer-Aided Molecular Design.

[57]  S Irle,et al.  Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19 , 2020, Journal of chemical information and modeling.

[58]  A. Mulholland,et al.  Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein , 2020, Science.

[59]  Amanat Ali,et al.  Dynamics of the ACE2–SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms , 2020, Scientific Reports.

[60]  P. Chaudhary,et al.  Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19 , 2021, Cells.

[61]  Mario J. Borgnia,et al.  Controlling the SARS-CoV-2 spike glycoprotein conformation , 2020, Nature Structural & Molecular Biology.

[62]  Mallikarjunachari V. N. Uppuladinne,et al.  Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2 , 2020, RSC advances.

[63]  Sean Ekins,et al.  Déjà vu: Stimulating open drug discovery for SARS-CoV-2 , 2020, Drug Discovery Today.

[64]  R. A. Silva,et al.  Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1). , 2020 .

[65]  G. Hummer,et al.  In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges , 2020, Science.

[66]  Peng Sang,et al.  Anti-HIV drug repurposing against SARS-CoV-2 , 2020, RSC advances.

[67]  T. Tripathi,et al.  Molecular Dynamics Simulation of Protein and Protein–Ligand Complexes , 2020 .

[68]  Rommie E. Amaro,et al.  A multiscale coarse-grained model of the SARS-CoV-2 virion , 2020, Biophysical Journal.

[69]  B. Luan,et al.  Enhanced binding of the N501Y‐mutated SARS‐CoV‐2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations , 2021, Febs Letters.

[70]  Naveen Vankadari Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence , 2020, The journal of physical chemistry letters.

[71]  Serena Dotolo,et al.  A review on drug repurposing applicable to COVID-19 , 2020, Briefings Bioinform..

[72]  Severin T. Schneebeli,et al.  Enhanced sampling protocol to elucidate fusion peptide opening of SARS-CoV-2 spike protein , 2021, Biophysical Journal.

[73]  Tom C.B. McLeish,et al.  Computational analysis of dynamic allostery and control in the SARS-CoV-2 main protease , 2020, bioRxiv.

[74]  P. Král,et al.  Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 , 2020, ACS nano.

[75]  Daniel A. Jacobson,et al.  Potentially adaptive SARS-CoV-2 mutations discovered with novel spatiotemporal and explainable AI models , 2020, Genome Biology.

[76]  Arpit Shukla,et al.  Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation , 2020, Biophysical Chemistry.

[77]  Gennady M Verkhivker,et al.  Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches , 2021, The journal of physical chemistry. B.